

Appl. No. 09/699,923  
Resp to Advisory Action dated April 25, 2005  
RCE filed November 1, 2005

## 2. Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

### Claims 1-14 (*Cancelled*)

Claim 15 (*Currently amended*) An *in vitro* method of preparing a dendritic cell population comprising the steps of:

- (a) contacting hematopoietic stem cells, or progenitor cells, or hematopoietic stem and progenitor cells with a growth factor or cytokine *in vitro*, wherein the growth factor or cytokine consists of flt3-ligand in an amount sufficient to generate a dendritic cell population;
- (b) exposing the dendritic cells to an antigen; and
- (c) allowing the dendritic cells to process and express the antigen.

Claim 16 (*Currently amended*) An *in vitro* method of preparing a dendritic cell population comprising the steps of:

- (a) contacting hematopoietic stem cells, or progenitor cells, or hematopoietic stem and progenitor cells with a growth factor or cytokine *in vitro*, wherein the growth factor or cytokine consists of flt3-ligand and GM-CSF in amounts sufficient to generate a dendritic cell population;
- (b) exposing the dendritic cells to an antigen; and
- (c) allowing the dendritic cells to process and express the antigen.

### Claims 17-22 (*Cancelled*)

Claim 23 (*Previously presented*) The method according to claim 15 wherein the flt3-ligand is human flt3-ligand.

Claim 24 (*Previously presented*) The method according to claim 16 wherein the flt3-ligand is human flt3-ligand.

Claim 25 (*Previously presented*) The method according to claim 16 wherein the GM-CSF is human GM-CSF.

### Claims 26-28. (*Cancelled*)

**BEST AVAILABLE COPY**

Appl. No. 09/699,923  
Resp to Advisory Action dated April 25, 2005  
RCE filed November 1, 2005

Claim 29 (*Currently amended*)      An *in vitro* method, comprising:  
    (a) collecting hematopoietic stem cells, progenitor cells, or hematopoietic stem and progenitor cells;  
    (b) ~~of preparing a dendritic cell population, the method comprising~~  
        contacting ~~the hematopoietic stem or progenitor~~ cells with a growth factor or cytokine *in vitro*, wherein the growth factor or cytokine consists of flt3-ligand;  
    and  
    (c) ~~in an amount sufficient to generate a dendritic cell population, thereby driving the cells to differentiate into generating a the dendritic cell population.~~

Claims 30-35 (*Cancelled*)

Claim 36 (*Previously presented*)      The method according to claim 29 wherein the flt3-ligand is human flt3-ligand.

Claim 37 (*Cancelled*)

Claim 38 (*Currently amended*)      The method of claims 15, 16, or 29, wherein the hematopoietic stem cells, or progenitor cells, or hematopoietic stem and progenitor cells have been enriched for the CD34+ phenotype.

BEST AVAILABLE COPY